Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | CCR5 | P51681 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | HTR2A | P28223 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11009706 | 0.81 | HSD11B1 (0.56) | HSD11B1ALDH1A1LMNASMN1; SMN2HTR2A | |
| SCHEMBL5760363 | 0.80 | HTR2A (0.61) | LMNASMN1; SMN2HTR2AKDM4ECYP1A2 | |
| SCHEMBL9378070 | 0.80 | HSD11B1 (0.57) | HSD11B1ALDH1A1LMNASMN1; SMN2HTR2A | |
| SCHEMBL9377800 | 0.78 | HSD11B1 (0.57) | HSD11B1ALDH1A1LMNASMN1; SMN2HTR2A | |
| SCHEMBL5757158 | 0.77 | HSD11B1 (0.54) | HSD11B1ALDH1A1LMNASMN1; SMN2HTR2A | |
| SCHEMBL7408128 | 0.76 | HSD11B1 (0.63) | HSD11B1ALDH1A1LMNASMN1; SMN2HTR2A | |
| Hydrochloric Acid SCHEMBL7404558 | 0.75 | HSD11B1 (0.61) | HSD11B1ALDH1A1LMNASMN1; SMN2HTR2A | |
| SCHEMBL5756913 | 0.75 | CYP2C19 (0.51) | HSD11B1ALDH1A1LMNASMN1; SMN2CYP1A2 | |
| SCHEMBL8669710 | 0.74 | HSD11B1 (0.58) | HSD11B1ALDH1A1LMNASMN1; SMN2HTR2A | |
| SCHEMBL10722200 | 0.73 | HTR2A (0.59) | HSD11B1LMNASMN1; SMN2HTR2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030105079-A1 | Novel phenylalkyl diamine and amide analogs | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2003-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105079-A1 | Novel phenylalkyl diamine and amide analogs | SIGMAR1, TAAR1, OPRL1 | HSD11B1 4412/4885ALDH1A1 639/4885CCR5 796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.